What Does COVID Look Like in the Throat?

COVID-19 in the throat typically shows up as widespread redness and swelling of the mucous membranes, sometimes accompanied by ulcers, white patches, or small spots of bleeding beneath the surface. The appearance can range from a mildly inflamed pink throat to an angry, deeply congested one depending on the variant involved and the person’s immune response. But what makes COVID throat distinctive is less about a single telltale visual sign and more about a pattern of features, including some that surprised researchers as the pandemic unfolded.

What the Throat Actually Looks Like During Infection

If you were to shine a light into the throat of someone with an active COVID infection, the most common finding is mucosal congestion and edema, meaning the lining of the throat looks swollen and deeply red. In a study comparing COVID-caused pharyngitis to pharyngitis from other pathogens, mucosal congestion and edema were identified as the most significant visual signs of COVID-related throat inflammation.¹ One detail that stood out: the tonsils often did not swell noticeably in COVID pharyngitis, which is different from what you’d expect with strep throat or many other common infections.

Beyond the redness, reviews cataloguing oral and throat changes in COVID patients have documented a surprisingly long list of lesions. These include ulcers, erosions, blisters, pustules, white patches and plaques, a depapillated tongue (where the surface looks unusually smooth), small hemorrhagic spots called petechiae, pigmentation changes, and spontaneous bleeding from the oral mucosa.²³ Not every patient develops all of these. Many people with mild COVID have a throat that looks fairly normal or just mildly pink. But in moderate to severe cases, the variety of oral and pharyngeal findings has been striking, even to ear-nose-and-throat specialists who see sore throats every day.

Why the Throat Is a Prime Target

SARS-CoV-2 enters cells by latching onto a receptor called ACE2 with the help of an enzyme called TMPRSS2. Both of these are found in abundance across the tissues of the mouth, throat, and pharynx. A systematic review of head and neck tissues found ACE2 expressed in multiple cell types throughout the oral and pharyngeal mucosa, including in the cells lining the surface, goblet cells, minor salivary gland cells, and the cells lining blood vessels.⁴ The virus has even been found replicating inside salivary gland cells, which can cause inflammation and shrinkage of those glands. This density of viral entry points helps explain why throat symptoms are so common and why the throat is one of the first sites where the virus establishes itself after exposure.

Omicron Changed the Throat Game

If you caught one of the early COVID strains in 2020, a sore throat was actually one of the less common symptoms. A systematic comparison found that only about 12% of COVID-19 patients reported sore throat with the original and early variants, compared to 84% of people with influenza or the common cold.⁵ That shifted dramatically with Omicron. One study found sore throat jumped to 66% of people infected with Omicron compared to 42% with earlier variants.⁶ Contact tracing data from England confirmed this pattern, showing sore throat was roughly twice as strongly associated with Omicron as with Delta.⁷

In some Omicron patients, the throat involvement went well beyond ordinary soreness. A case series from Sweden documented patients presenting to emergency departments with acute odynophagia, meaning severe pain on swallowing. All patients in that series had intense throat pain as their primary complaint, and about a third also had hoarseness. Some developed signs of secondary bacterial infection in the throat, and one in five needed to be hospitalized specifically for management of their throat symptoms, including one patient with significant swelling of the tissue around the vocal cords.⁸ This was a newer and more aggressive throat presentation than what clinicians had seen with earlier waves.

With Delta, sore throat was present but less dominant. A study of Delta-variant patients found that among those who had pain complaints, throat pain and fatigue scored highest on patient-reported pain scales, with a median severity rating of 6 out of 10 for both.⁹ So Delta could produce meaningful throat pain, but it wasn’t the leading symptom the way it became with Omicron.

How COVID Throat Differs From Strep, Flu, and the Common Cold

One of the trickiest aspects of COVID throat symptoms is that they overlap with almost everything else. A red, sore throat is the hallmark of dozens of infections. But there are patterns worth knowing. In the pre-Omicron era, COVID was actually less likely to cause sore throat than the flu or a cold. The same systematic comparison that found sore throat in just 12% of early COVID patients found it in 84% of both influenza and common cold patients.⁵ A head-to-head comparison between COVID and influenza during a local cluster found sore throat in 44% of flu patients but only 20% of COVID patients in the same community.¹⁰ With Omicron, that gap closed substantially, making visual or symptom-based distinction harder.

One clinically useful clue: COVID pharyngitis tends to produce diffuse mucosal redness and swelling without the pronounced tonsil enlargement you’d see with bacterial pharyngitis like strep. A diagnostic panel for Omicron pharyngitis found that the combination of mucosal congestion, edema, and the absence of tonsil swelling had high diagnostic efficiency for distinguishing COVID from other causes of sore throat.¹ Strep throat, by contrast, classically presents with red, swollen tonsils that may have white pus patches, often with tiny red spots on the roof of the mouth. COVID’s redness tends to be more uniformly spread across the back of the throat rather than concentrated on the tonsils.

That said, none of these visual differences are reliable enough to substitute for testing. The throat can look identical across multiple infections, and COVID can occasionally cause tonsil involvement too. Clinicians use these patterns as one data point alongside testing, not as a standalone diagnostic tool.

Testing From the Throat

The shift toward more throat-centered infection with Omicron also affected how well different swabbing methods work. A study of over 800 participants found that for detecting the Omicron variant by PCR, throat-only swabs actually had a sensitivity of 97% compared to 91% for nose-only swabs, when measured against a combined nose-and-throat approach.¹¹ However, there was a catch: viral concentrations in throat swabs declined more quickly over time than in nasal swabs, meaning that if you wait several days into symptoms, the nose may actually be the more reliable site.

For rapid antigen tests (the kind most people use at home), the picture is a bit different. One study found that nasal or throat swabs each picked up only about 65% of confirmed cases when used alone, but combining both swabs boosted detection to nearly 89%.¹² This is why some public health guidance during the Omicron waves shifted to recommending a combined swab approach. If your rapid test kit’s instructions allow it, swabbing both your throat and nose with the same swab gives you the best chance of an accurate result, especially early in infection when the virus may be more concentrated in the throat than the nose.

Voice Changes and What They Reveal

Many people with COVID notice that their voice sounds off. This is more than just the scratchiness you’d expect from any sore throat. A meta-analysis covering nearly 14,000 patients found that roughly one in four COVID patients experienced dysphonia, meaning a noticeable change in voice quality, during their acute infection.¹³ The changes ranged from mild hoarseness to complete loss of voice. Patients who developed dysphonia also tended to have worse throat pain, more difficulty swallowing, and more shortness of breath compared to patients without voice changes.¹⁴

When specialists looked at the vocal cords of these patients using a tiny camera threaded into the throat (videolaryngoscopy), the findings were varied and sometimes alarming. The most common observations included vocal cord paralysis on one side, redness of the laryngeal tissue, muscle tension dysphonia, granulomas (small inflammatory lumps), edema, and even some cases of stenosis, which is narrowing of the airway.¹⁵ The vocal cord paralysis findings were particularly telling because they suggested the virus could damage the vagus nerve, which controls the muscles of the larynx.

When Throat Symptoms Linger After Recovery

For most people, COVID throat symptoms resolve within a week or two. But a meaningful minority deal with lingering problems. That same meta-analysis on dysphonia found that voice changes persisted in about 17% of patients after the acute infection cleared, and roughly one in five patients experienced what the researchers classified as long-COVID dysphonia.¹³ A systematic review of persistent ear, nose, and throat problems after COVID recovery found that sore throat, hoarseness, difficulty swallowing, dry cough, and the sensation of something stuck in the throat were all widely reported among long-COVID patients.¹⁶

Research into why these symptoms persist has pointed to nerve damage. A study using laryngeal electromyography on patients with persistent throat symptoms after COVID found that the most common complaint was periodic hoarseness of varying severity, along with the feeling of a foreign body in the throat and voice fatigue. Electrical recordings of the cricothyroid muscle (one of the muscles that controls vocal pitch) showed abnormal activity in all tested patients, consistent with a sensory nerve problem in the larynx.¹⁷ Separate research found electrical evidence of vagus nerve damage in patients with chronic cough after COVID, further supporting the idea that the virus can leave lasting damage to the nerves controlling the throat and airway.¹⁸

What Happens to the Throat’s Microbial Ecosystem

Your throat is home to a diverse community of bacteria that, under normal circumstances, lives in balance. COVID disrupts that balance. Studies of the upper respiratory microbiome during infection found a consistent pattern: beneficial bacteria decline while potentially harmful opportunistic bacteria increase.¹⁹ One study tracking the respiratory microbiome over the course of COVID illness found that as infection progressed, bacterial diversity dropped and opportunistic species, including nonpathogenic Pseudomonas, became dominant.²⁰ A meta-analysis of oral and throat microbiome studies in COVID patients identified Neisseria species as a potentially key bacterial member associated with infection.²¹

This microbial disruption matters because it opens the door to secondary bacterial infections. Although the overall rate of bacterial co-infection in COVID patients is relatively low, those who develop secondary infections tend to have significantly worse outcomes, including longer hospital stays and higher rates of ICU admission.²² In patients with severe COVID, dominant pathogenic bacteria were detected in about 41% of upper respiratory samples and 63% of lower respiratory samples, compared to only about 11% and 9%, respectively, in patients with mild disease. The most common culprits included Staphylococcus, Corynebacterium, and Acinetobacter species.²³ In a separate hospital study, about 12% of COVID patients developed secondary bacterial infections, with Klebsiella species being the most commonly isolated.²⁴

The Tonsils as an Immune Battleground

The tonsils sit right at the back of the throat and serve as one of the body’s early-warning immune stations. Research has shown that SARS-CoV-2 doesn’t just pass through this tissue but actively establishes itself there. A study of tonsil tissue from children found that tonsils were major sites where the virus persisted, and that infection of immune cells within the tonsils, including B cells, T cells, and macrophages, could interfere with the immune response that these tissues are supposed to mount.²⁵

On the flip side, the tonsils also mount a surprisingly robust defensive response. Researchers detected both virus-specific germinal center B cells and T follicular helper cells in human tonsils early after SARS-CoV-2 infection, indicating that the tonsils actively generate immune responses and could contribute to long-term immunity.²⁶ So the tonsils play a dual role: they’re both a reservoir where the virus can linger and a factory for building immunity against it.

The throat’s mucosal lining also produces its own antibodies in the form of secretory IgA, which showed up in throat swabs within about four days of symptom onset in COVID patients and reached a 100% detection rate by the second to third week of illness.²⁷ This local antibody production is part of why researchers have been interested in developing nasal and oral vaccines that could boost mucosal immunity right at the site where infection begins, potentially stopping the virus before it can spread deeper into the lungs.

1
PubMed Central. Clinical characteristics and diagnostic panel for Omicron pharyngitis
2
PubMed Central. Oral manifestations of COVID-19 disease: A review article
3
PubMed Central. Oral Lesions Associated with COVID-19 and the Participation of the Buccal Cavity as a Key Player for Establishment of Immunity against SARS-CoV-2
4
PubMed Central. Long-Term Post-COVID-19 Associated Oral Inflammatory Sequelae
5
Advances in Clinical and Experimental Medicine. Comparison of the clinical differences between COVID-19, SARS, influenza, and the common cold: A systematic literature review
6
PubMed Central. Association between sore throat and early immune responses against COVID-19 before and after the emergence of the Omicron variant
7
PubMed Central. Comparative symptomatology of infection with SARS-CoV-2 variants Omicron (B.1.1.529) and Delta (B.1.617.2) from routine contact tracing data in England
8
PubMed Central. Acute odynophagia: A new symptom of COVID‐19 during the SARS‐CoV‐2 Omicron variant wave in Sweden
9
Frontiers in Pain Research. Clinical manifestations of pain in patients suffering from COVID-19 infected with Delta variant of SARS-Cov-2
10
PubMed Central. Clinical features of COVID-19 and influenza: a comparative study on Nord Franche-Comte cluster
11
PubMed. Comparative evaluation of swabbing sites for Omicron variant detection in PCR testing
12
PubMed Central. Investigating the Sensitivity of Nasal or Throat Swabs: Combination of Both Swabs Increases the Sensitivity of SARS-CoV-2 Rapid Antigen Tests
13
PubMed Central. COVID-related dysphonia and persistent long-COVID voice sequelae: A systematic review and meta-analysis
14
PubMed. Features of Mild-to-Moderate COVID-19 Patients With Dysphonia
15
Journal of Voice. Dysphonia and COVID-19: A Review
16
PubMed Central. Persistent ENT Manifestations in Individuals who Recovered from COVID-19: A Systematic Review
17
PubMed Central. Laryngeal sensory neuropathy caused by COVID-19: findings using laryngeal electromyography
18
PubMed Central. Chronic cough in post-COVID syndrome: Laryngeal electromyography findings in vagus nerve neuropathy
19
PubMed Central. Potential Associations Between Microbiome and COVID-19
20
Communications Biology. Temporal association between human upper respiratory and gut bacterial microbiomes during the course of COVID-19 in adults
21
PubMed. COVID-19 associated oral and oropharyngeal microbiome: Systematic review and meta-analysis
22
PubMed Central. Coronavirus disease 2019 (COVID-19): Secondary bacterial infections and the impact on antimicrobial resistance during the COVID-19 pandemic
23
PubMed Central. Super Dominant Pathobiontic Bacteria in the Nasopharyngeal Microbiota Cause Secondary Bacterial Infection in COVID-19 Patients
24
PubMed Central. Bacterial co-infections and antibiotic resistance in patients with COVID-19
25
PubMed Central. Tonsils are major sites of persistence of SARS-CoV-2 in children
26
The Journal of Immunology. Cutting Edge: SARS-CoV-2 Infection Induces Robust Germinal Center Activity in the Human Tonsil
27
PubMed Central. Respiratory Mucosal Immunity: Kinetics of Secretory Immunoglobulin A in Sputum and Throat Swabs From COVID-19 Patients and Vaccine Recipients